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Abstract
Background: We have shown previously that microvesicle (MV)-delivered miR-130b (miR-130b-MV) is able to target
PPAR-γ and subsequently reduce the lipid accumulation in vitro. However, the in vivo effect of miR-130b on fat
deposition and glucose homeostasis remains unknown.
Results: Three-week-old C57BL/6 mice were fed a high-fat diet for 8 weeks and then intravenously injected with
MV-packaged scrambled control microRNA (miRNA) or miR-130b every other day for 10 days. Glucose tolerance test
was performed and body weight, epididymal fat weight, as well as the expression of lipid metabolic genes were
determined. We showed that mice fed on high-fat diet for 8 weeks demonstrated significantly higher body weight,
elevated blood glucose and impaired glucose tolerance. miR-130b-MV injection significantly reduced body weight
and epididymal fat weight and partly restored glucose tolerance. miR-130b expression was significantly increased in
the epididymal fat after miR-130b-MV injection while the protein content of its target gene PPAR-γ was significantly
suppressed, together with a significant up-regulation of the lipolysis genes, hormone sensitive lipase, monoglyceride
lipase and leptin. Moreover, miR-130b-MV injection increased the expression of miR-378a and miR-378-3p that are
reported to participate in the regulation of fat deposition.
Conclusion: Our results indicate that miR-130b-MV is able to reduce the epididymal fat deposition and partly restore
glucose tolerance, through translational repression of PPAR-γ in a high-fat diet-induced obese mouse model.
Keywords: MV-delivery miR-130b, PPAR-γ, Lipolysis, Epididymal fat deposition, High-fat diet induced obese mice
Background
Obesity is a major risk factor for the development of
type II diabetes (T2DM), cardiovascular diseases, and
some types of cancer [1–5]. Searching for more efficient
and safe approaches to prevent and treat obesity has
been the focus of intensive research. Peroxisome prolifera-
tor activated receptor gamma (PPAR-γ) is a ligand acti-
vated transcription factor which is regarded as a master
regulator of fat deposition [6–8]. Previous studies have
shown that activation or over-expression of PPAR-γ can
stimulate lipogenesis and adipogenesis [1], while down-
regulation of PPAR-γ decreases fat mass in mice [9–13].
Therefore, PPAR-γ is considered as a therapeutic target
for the treatment of obesity.
MicroRNAs (miRNAs) are small non-coding RNAs
which regulate gene expression through mRNA degradation
and/or translational repression [14]. Numerous studies
have demonstrated that some miRNAs can inhibit PPAR-
γ expression and suppress adipogenesis and lipogenesis.
Both miR-302a and miR-27a are reported to inhibit adipo-
genic differentiation and lipid accumulation in 3T3-L1
mouse adipocytes [15] and human multipotent adipose-
derived stem cells [16] by down-regulating PPAR-γ ex-
pression. miR-130 has been shown to strongly reduce
adipogenesis by repressing PPAR-γ biosynthesis in human
primary preadipocytes and 3T3-L1 mouse adipocytes
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[17]. These findings suggest that miRNAs may be used
as an effective therapy for the treatment of obesity. How-
ever, exogenous miRNAs without appropriate protection
or modifications can be quickly degraded by RNases that
are abundant in the blood [18]. Therefore, the stability of
exogenous miRNAs is one of the primary concerns with
respect to clinical application [19].
Microvesicles (MVs) are a heterogeneous population
of membrane-covered vesicles ranging from 100 nm to
1 μm in diameter, being secreted by almost all types of
cells in vivo and in vitro under both normal and patho-
logical conditions [20–23]. MVs are able to protect, trans-
port and deliver bioactive contents, including miRNAs
[24], from parent cells to cells of other origins [25, 26]. Re-
cently, we demonstrated that miR-130b can be packaged
into MVs and delivered to the recipient primary cultured
porcine adipocytes to reduce lipid accumulation in vitro
by inhibiting PPAR-γ expression [27] . Nevertheless, it
remains unknown whether MV-shuttled miR-130b can
modulate fat deposition through targeting PPAR-γ in vivo.
Therefore, in the present study, we tested anti-obesity
efficacy of MV-packaged miR-130b on a high-fat diet-
induced C57BL/6 mouse model. miR-130b was packaged
into MV by HeLa-229 cells transfected to over-express
exogenous miR-130b. MV-packaged miR-130b was iso-
lated from the culture media through ultracentrifugation
and was injected intravenously to the obese mice. We
show that miR-130b was delivered to the epididymal fat
tissue and significantly decreased the fat deposition, which
was associated with a significant down-regulation of
PPAR-γ protein content and an activation of lipolytic
genes. Our results provide the preliminary evidences
that MV-mediated delivery of miR-130b is able to reduce
fat deposition in a high-fat diet-induced obese model.
Methods
Reagents, cells, and antibodies
Dulbecco's modified Eagle's medium: Nutrient Mixture
F-12 (DMEM/F-12) was supplied by Life Technologies
Inc. (Carlsbad, CA, USA). Fetal bovine serum (FBS) was
obtained from HyClone (Logan, UT, USA). The human
cervix cancer cell line HeLa-229 was purchased from the
Cell Resource Center of Shanghai Institute for Biological
Sciences, Chinese Academy of Sciences (Shanghai, China).
Anti-PPAR-γ (BS4444, 1: 500 dilution) and anti-GAPDH
antibodies (AP0066, 1: 10,000 dilution) were purchased
from Bioworld Technology (Minneapolis, MN, USA).
Synthetic RNA molecules and scrambled negative control
oligonucleotides were purchased from Life Technologies
Inc..
Plasmid construction
The precursors of miR-130b (89 bp) and the negative con-
trol miRNA (Scrambled control, miR-SC) were synthesized
by Life Technologies Inc., based on the sequence infor-
mation from miRNA precursors (www.mirbase.org) and
the requirements for pSilencer 3.1-H1 siRNA expression
vector (Ambion, Austin, TX, USA). Precursors of miR-130b
and miR-SC were produced by annealing the upstream and
downstream (50 μmol/L each) miRNA precursor sequences
(Table 1). The 50 μL reaction mix was incubated in 96-well
plates at 95 °C for 2 min, and subjected to touchdown PCR.
During this procedure the temperature was decreased
0.1 °C every 8 s until it reached 25 °C. The PCR products
were subcloned into pSilencer 3.1-H1 siRNA expression
vector using BamHI and HindIII restriction endonucleases
(Life Technologies Inc.).
Cell culture, miR-130b transfection and microvesicle
isolation
Approximately 3 × 105/cm3 HeLa-229 cells were seeded
in 150 mm cell culture dish and grown in DMEM/F-12
media supplemented with 15 mmol/L NaHCO3, 100 IU/mL
penicillin, 100 IU/mL streptomycin, and 10 % FBS at 37 °C
in a 5 % CO2, water-saturated incubator. When the cells
reached 90-95 % confluence, plasmids of 50 μg miR-130b
and 50 μg miR-SC were transfected separately with Lipofec-
tamine 2000 (Life Technologies Inc.), according to the man-
ufacturer’s instructions. The transfected cells were incubated
at 5 % CO2 and 37 °C. Four hours later, the transfection
medium was changed to DMEM/F-12 containing 10 %
MVs-free FBS prepared by ultracentrifugation and filtra-
tion [28]. Cells were harvested 24 h after transfection and
the medium was collected.
MVs were isolated from the medium by differential cen-
trifugation according to previously published methods [29].
Briefly, 18 mL media mixture from six dishes was sub-
jected to serial centrifugation. Initial centrifugation was
undertaken at 300 g for 10 min followed by 1200 g for
10 min and 10,000 g for 20 min, by this process dead
cells and other debris were removed. Then the resulting
supernatant was filtered through 0.22 μm filters (Millipore,
Billerica, MA, USA) into Beckman Quick seal tubes. Ultra-
centrifugation was performed at 110,000 g for 2 h using a
70Ti rotor (Beckman Coulter, Brea, CA, USA). All steps
were performed at 4 °C. MVs were collected from the
pellets and re-suspended in FBS-free media for subse-
quent assay. The Bicinchoninic acid (BCA) method was
used to quantify the total protein concentration in MVs
preparations.
Animals and diets
All procedures involving laboratory animal use were ap-
proved by the Animal Ethics Committee of Nanjing Agricul-
tural University, with the project number 2012CB124703.
The slaughter and sampling procedures complied with the
“Guidelines on Ethical Treatment of Experimental Animals”
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(2006) No. 398 set by the Ministry of Science and Technol-
ogy, China.
Three-week-old male specific pathogen-free (SPF) C57BL/
6 mice weighing 9 ~ 10 g were obtained from the Com-
parative Medicine Center of Yangzhou University (Yang-
zhou, China, certificate of quality is SCXK (Su) 2012-0004)
and fed in the Laboratory Animal Center of Jiangsu Prov-
ince Integrative Medicine Hospital. The mice were housed
in standard cages (33 × 23 × 12 cm, five mice/cage), main-
tained under controlled conditions (22 ± 0.5 °C, 50 ± 5 %
relative humidity, 12-h/12-h dark/light cycle) with free
access to both food and water.
After 7-day adaptation, thirty-six mice were randomly
divided into two groups as follows: (1) the control group
(MD10% fat group, n = 12) fed with normal fat diet
(MD12031, 10 % fat); (2) the high fat group (MD45% fat
group, n = 24) fed with high-fat diet (MD12032, 45 %
fat). Both control and high fat diets were purchased from
Medicience Ltd. (Yangzhou, China). The diets were re-
placed every 2 days to prevent oxidization of the fats in
diets. After 8 weeks, the body weight was recorded and
the glucose tolerance test was performed to confirm the
successful establishment of the obese mouse model.
Then, we divided the obese mice randomly into two
groups: (1) the control group injected with miR-SC-MV
(HF-SC-MV); (2) the treated group injected with miR-
130b-MV (HF-130b-MV). The mice were injected every
other day for 10 days. During the 10 days of treatment,
the mice in both groups were still fed high-fat diet.
Oral glucose tolerance test (OGTT)
After 10 h fasting (from 8:30 in the morning till 18:30 in
the afternoon), the mice were given glucose at 2.5 g/kg
body weight by intraperitoneal injection. The blood glu-
cose levels before glucose injection (0 min) and 15, 30, 60,
90, 120 min after glucose injection were determined.
Preparation of blood and epididymal fat tissue
After ten days of treatment, the mice were fasted for
10 h and the body weight was recorded. Then the blood
























PPAR-γ (NM_138711) F: GCCCTTCACCACTGTTGATT
R: GAGTTGGAAGGCTCTTCGTG
GR (AY779185) F: CCAAACTCTGCCTTGTGTGTTC
R: TGTGCTGTCCTTCCACTGCT
TNF-α (NM_013693.3) F: CTATGGCCCAGACCCTC
R: GCAGCCTTGTCCCTTGA
UCP-3 (NM_009464.3) F: ACGATGGATGCCTACAGGAC
R: TCCGAAGGCAGAGACAAAGT
LDLR (NM_001252658.1) F: TCAGTCCCAGGCAGCGTAT
R: TGATCTTGGCGGGTGTT
STAT3 (NM_011486.4) F: ATTGTGATGCCTCCTTGA
R: ATTGGCGGCTTAGTGAA
FAS (EF589048) F: GTCCTGCTGAAGCCTAACTC
R: TCCTTGGAACCGTCTGTG
SCD-1 (NM_213781) F: CCCAGCCGTCAAAGAGAA
R: CGATGGCGTAACGAAGAAA
11β-HSD1 (AF414124) F: CCATGCTGAAGCAGAGCAAC
R: AAGAACCCGTCCAGAGCAAA
HSL (AY686758) F: ACCCTCGGCTGTCAACTTCTT
R: TCCTCCTTGGTGCTAATCTCGT
ATGL (EF583921) F: ACCTGTCCAACCTGCTGC
R: GCCTGTCTGCTCCTTTATCCA
MGL (NM_001166249.1) R: CATTGCTCGCTCCACTCTT
F: ATGGTCCTGATTTCACCTCTG
Leptin (NM_008493.3) F: CCCTCATCAAGACGATTGTCA
Table 1 Primers used for plasmids construction and mRNA
quantification (Continued)
R: GGTTCTCCAGGTCATTCGATA
LeptinR (NM_001122899.1) F: CCCTCATCAAGACGATTGTCA
R: GGTTCTCCAGGTCATTCGATA
ACC (NM_133360.2) F: AGCAGTTACACCACATACAT
R: TACCTCAATCTCAGCATAGC
SREBP-1 (NM_011480.3) F: GCTTCTCTTCTGCTTCTCT
R: GCTGTAGGATGGTGAGTG
PPIA (NM_214353.1) F: TCCTCCTTGGTGCTAATCTCGT
R: TGATCTTCTTGCTGGTCTT
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was drawn from the abdominal aorta using a syringe.
The plasma was separated by centrifugation at 3000 rpm
for 15 min at 4 °C and stored at -20 °C. The epididymal
fat, gastrocnemius muscle and liver samples were removed,
weighed and snap-frozen in liquid nitrogen and then
stored at -70 °C.
Analyses of plasma biochemical parameters, hormones
and cytokines
Plasma concentrations of biochemical metabolites, includ-
ing alanine transaminase (ALT, no.C009-2), aspartate
transaminase (AST, no.C010-1), glucose (GLU, no.F006),
triglycerides (TG, no.F001-1), total cholesterol (TCh,
no.F002-1), high-density lipoprotein cholesterol (HDLc,
no.A112-2), low-density lipoprotein cholesterol (LDLc,
no.A113-1) and nonestesterified fatty acid (NEFA, no.A042-1)
were detected by automatic biochemical analyzer
(Beckman coulter, AU2700) using commercial kits
(Jiancheng Bioengineering Institute, Nanjing, China).
The plasma concentrations of hormones and cytokines,
such as interleukin-6 (IL-6, no.96-407), insulin (no.96-416),
leptin (no.96-421) and tumor necrosis factor (TNF-α,
no.96-422), were measured by China Biomarker Service,
Luminex 200 (no.CNBMSLX200) using Magnetic Bead
MAPmate (Merck&Millipore, Darmstadt, Germany) ac-
cording to the instructions provided by the manufacturer.
RNA isolation and mRNA quantification
Total RNA was isolated from liver using Trizol reagent
(Life Technologies Inc.), according to the manufacturer’s
instructions. Concentration of the extracted RNA was
measured using a NanoDrop-1000 spectrophotometer.
RNA integrity was confirmed by denaturing agarose elec-
trophoresis, and DNA contamination was evaluated by
PCR using isolated RNA as template with the primers
of 18s. M-MLV (Promega, Madison, WI, USA) and dN6
random primer (Takara, Kyoto, Japan) were used to
synthesize cDNA from 2 μg of total RNA from each
sample according to manufacturer’s instructions. Three
reference genes (PPIA, GAPDH and 18s) were tested
and the mRNA abundances showed no difference between
the two groups, and at last PPIA was chosen as a refer-
ence gene. Real-time PCR was performed in Mx3000P
(Stratagene, Palo Alto, CA, USA). All primers used for
this experiment were listed in Table 1.
miRNAs real-time PCR quantification
Total RNA was treated with RNase-free, DNase I (TaKaRa).
The total RNA (4 μg) was polyadenylated by poly (A) poly-
merase at 37 °C for 1 h in a 20 μL reaction mixture using a
Poly (A) tailing kit (AM1350, Applied Biosystems, Carlsbad,
CA, USA) according to the manufacturer’s instructions.
The polyadenylated RNA was then dissolved and re-
verse transcribed using the poly (T) adapter.
Real-time PCR was performed, in triplicate, using the
SYBR green qPCR master mix reagent (Takara) with a
miRNA-specific forward primer and a universal reverse
primer that is complementary to part of the poly (T)
adapter sequence. Since no validated reference gene was
available for pig miRNAs, a random DNA oligonucleotide
was added to RNase-free DNase I-treated total RNA
samples before polyadenylation, as an exogenous reference,
to normalize the expression of miRNAs. The sequences of
all the mature miRNAs, the poly (T) adapter and the
exogenous reference gene used in the present study are
listed in Table 2.
Determination of PPAR-γ protein content
Total protein was extracted from the epididymal adipose
tissue and the protein concentration was measured using
a BCA protein assay kit (Pierce, Rockford, IL, USA) ac-
cording to the manufacturer’s instructions. Protein extracts
(30 μg) were used for electrophoresis on a 12 % SDS-
PAGE gels. Western blot analysis for detecting PPAR-γ
was undertaken according to the protocols provided by
the manufacturer. GAPDH was used as a reference.
Statistical analysis
All data are presented as means and standard errors (±
SEM). For oral glucose tolerance test, the general linear
model (univariate) was conducted to evaluate the effects
of miR-130b-MV injection and the injection time point, as
well as their interactions. The differences between two
groups were tested using one-way analysis of variance
Table 2 primers used for miRNA detection













poly(T) adapter TAGAGTGAGTGTAGCGAGCACAGAA N/A
TTAATACGACTCACTATAGGTTTTTT
TTTTTTTTTTVN
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(ANOVA). All statistical analyses were undertaken using
Statistical Program for Social Sciences (SPSS) version 18.0
for Windows (SPSS Inc., Chicago, IL, USA). The level of
significance was set at P < 0.05.
Results
Establishment of high-fat diet-induced obese mouse
model
C57BL/6 obese mouse model was successfully established
after feeding high-fat diet ad libitum for 8 weeks (Fig. 1).
The experimental design for establishing the obese mice
model is depicted in a flow chart (Fig. 1a). The body
weight was significantly higher (P < 0.01) in high-fat diet
group (Fig. 1b-c) with significantly increased (P < 0.05)
body weight gain (Fig. 1d). The oral glucose tolerance test
(OGTT) demonstrated impaired glucose tolerance in
high-fat diet group as compared with the control group
(Fig. 1e), which was indicated by significantly increased
(P < 0.001) area under the blood glucose-time curve
(AUC) (Fig. 1f ).
miR-130b-MV partly restored glucose tolerance
To determine the effects of miR-130b-MV injection on the
glucose tolerance, OGTT was performed (Fig. 2). Blood
glucose concentrations in miR-130b-MV-injected mice
were significantly reduced (P = 0.003) after the intravenous
injection of glucose (2.5 g/kg body weight) when com-
pared with miR-SC-MV-injected mice (Fig. 2a). In
addition, miR-130b-MV injection tended to reduce (P =
0.057) the AUC when compared with miR-SC-MV-
injected mice (Fig. 2b). The above results suggest that
intravenous injection of miR-130b-MV partly restored the
glucose tolerance caused by high-fat diet.
miR-130b-MV reduced body weight and epididymal fat
weight
The protocol of MV injection via tail vein is depicted in
the flow chart (Fig. 3a). We delivered miR-130b-MV to
assess the anti-obesity effect of miR-130b in vivo. The
HeLa-229 cell expresses very low level of miR-130b [27],
so it was chosen to serve as a carrier host for the over-
expression of exogenous miR-130b. HeLa-229 cells were
transfected with the miR-130b over-expression plasmid,
while plasmid over-expressing miR-SC was also transfected
to serve as a negative control. MVs containing miR-130b
and miR-SC were purified from the supernatant of
transfected cells and RT-PCR verified the package of
significantly higher levels of miR-130b in miR-130b-MV
preparations (Fig. 3b). miR-130b-MV and miR-SC-MV
preparations were injected via tail vein into the obese mice
of treatment and control groups respectively every other
day for 10 days. The phenotypic changes in body size
and fat deposition are shown in Fig. 3c-e, which indicate
obviously reduced body weight and the epididymal fat
mass in mice treated with miR-130b-MV.
Quantitatively, miR-130b-MV significantly reduced the
body weight (P < 0.01), the epididymal fat weight (P < 0.05)
(Fig. 3f) and the muscle weight (P < 0.05), but not the liver
weight. Furthermore, the epididymal fat weight relative to
the body weight tended to be lower (P = 0.063) (Fig. 3g) in
miR-130b-MV group when compared with miR-SC-MV
group. The relative muscle weight was not different, yet
the liver weight relative to the body weight was signifi-
cantly higher (P < 0.05) in miR-130b-MV group compared
with miR-SC-MV counterparts (Table 3).
miR-130b-MV treatment did not affect the plasma con-
centrations of ALT, AST, Tch, HDLc, LDLc, IL-6, insulin,
leptin or TNF-α, while TG (P = 0.109) and glucose (P =
0.074) concentrations tended to be lower in miR-130b-
MV group (Table 3).
miR-130b-MV increased miR-130b expression and sup-
pressed PPAR-γ protein content in epididymal fat
The abundance of miR-130b in the epididymal fat tissue
was significantly higher (P < 0.05) in HF-130b-MV group
(Fig. 3h). The mRNA expression of the predicted target
genes of miR-130b, including GR, TNF-α, UCP-3, SCD-1,
LDLR, STAT3, and PPAR-γ (Fig. 3i), was detected and
only PPAR-γ tended to be increased (P = 0.07, Fig. 3j)
in miR-130b-MV group. However, the protein content
of PPAR-γ was significantly reduced (P < 0.05) in the epi-
didymal fat of mice injected with miR-130b-MV (Fig. 3k).
miR-130b-MV affected mRNA expression of lipid metabolic
genes in epididymal fat
Injection of miR-130b-MV affected the expression of lipid
metabolic genes in the epididymal fat of high-fat diet-
induced obese mice (Fig. 4). Hormone sensitive lipase
(HSL) and monoacylglycerol lipase (MGL), the two lipo-
lytic enzymes, as well as leptin, the appetite suppressing
adipokine, were significantly up-regulated (P < 0.01) in the
epididymal fat of high-fat diet-induced obese mice. The
mRNA expression of adipose triglyceride lipase (ATGL)
tended to be higher (P = 0.07) in miR-130b-MV-injected
mice while the mRNA expression of leptin receptor was
not affected.
Moreover, miR-130b-MV did not affect the mRNA
expression of CCTTA enhancer binding protein-β (C/
EBP-β), peroxisome proliferators-activated receptor-α
(PPAR-α), sterol regulatory element-binding protein 1
(SREBP1), or the lipogenic enzymes, fatty acid synthase
(FAS) and acetyl-CoA carboxylase (ACC). However,
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
mRNA expression was significantly up-regulated (P < 0.01)
in miR-130b-MV-injected mice when compared with
miR-SC-MV mice (Fig. 4).
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Fig. 1 (See legend on next page.)
Pan et al. Journal of Biomedical Science  (2015) 22:86 Page 6 of 12
miR-130b-MV affected expression of other miRNAs
involved in lipid metabolism in epididymal fat
The abundance of 11 other miRNAs in the epididymal
fat that are closely related to fat deposition was also de-
termined. The expression of miR-378a and miR-378b-3P
was significantly increased (P < 0.05) in the epididymal
fat of miR-130b-MV-injected mice when compared with
miR-SC-MV-injected mice (Fig. 5).
Discussion
High-fat induced obese C57BL/6 mice have been widely
used as a model for studying human visceral obesity
because they represent the human simple obesity both
metabolically and pathophysiologically [30–32] . In this
study, feeding C57BL/6 mice with high-fat diet for
8 weeks significantly increased the body weight by over
20 %, indicating that the obese mice model was suc-
cessfully established [33]. Furthermore, blood glucose
concentration was also significantly increased, suggesting
impaired glucose tolerance which is closely associated
with obesity [34].
In our previous study, we demonstrated that miR-130b-
MV was able to reduce the lipid deposition in porcine
primary adipocytes in vitro by targeting PPAR-γ gene
[27]. Here we provide the evidence that miR-130b-MV
injection was effective to decrease body weight and
reduce epididymal fat deposition in high-fat diet-
induced obese mice in vivo, at least partly through the
translational repression of PPAR-γ. This is in agreement
with a previous observation that miR-150-MV injection
suppressed its target c-Myb expression and enhanced cell
migration in mice [35] . Similarly, it was reported that
miR-143-MV injection via tail vein was able to suppress
tumor growth in mice [36]. Although there have been
several attempts to administer MV-shuttled miRNAs by
intravenous injection, this study provides, to our know-
ledge, the first evidence that miRNA packaged in MVs
has an anti-obesity efficacy in an in vivo animal model.
However, the safety of miR-130b-MV-mediated therapy
for obesity has to be considered. In the present study,
we inspected histologically the possible side effects of
miR-130b-MV on other tissues, including liver, kidney,
heart and spleen. No obvious pathological changes were
observed (H&E results not shown). Based on the con-
sideration that each miRNA may target multiple target
genes and function through different pathways [37], we
detected numerous biochemical and hormonal param-
eters in the plasma including ALT, AST, Tch, TG, glu-
cose, HDLc, LDLc, IL-6, insulin, leptin, and TNF-α.
Interestingly, none of these blood parameters showed
significant change, except TG and glucose displayed a
tendency of decrease. This indicates that the general
metabolic homeostasis of the body was not disturbed
by miR-130b-MV treatment. Moreover, GR, TNF-α, UCP-3,
SCD-1, LDLR, and STAT3, in addition to PPAR-γ, are
also predicted to be the target of miR-130b, yet the
Fig. 2 Mean blood glucose levels following OGTT. Mice were fasted 10 h and glucose was administered by intraperitoneal injection at 2.5 g/kg
body weight. a: Mean blood glucose levels following OGTT. b: Area under the blood glucose-time curve (AUC). OGTT, oral glucose tolerance test;
HF, high fat; HF-SC-MV, high-fat diet-induced obese mice injected with miR-SC-MV; HF-130b-MV, high-fat diet-induced obese mice injected with
miR-130b-MV; The values shown represent the means ± SEM, n = 12; P < 0.01 vs. HF-SC-MV group
(See figure on previous page.)
Fig. 1 Establishment of high-fat diet-induced obese mouse model. a: Flow chart depicting the experimental design. Three-week-old C57BL/6 mice
were fed with a normal fat diet (MD10% group) or a high fat diet (MD45% group) for 8 weeks. The obese mice model was confirmed by detecting
body weight and OGTT. b: Body weight of C57BL/6 mice after feeding high-fat diet for 8 weeks. c: Phenotype of C57BL/6 mice. d: Changes in body
weight in C57BL/6 mice during 8 weeks’ high-fat diet feeding. e: Mean blood glucose levels following OGTT. f: Area under the blood glucose-time
curve (AUC). MD10%, 10 % fat medicience diet, normal fat diet group; MD45%, 45 % medicience diet, high-fat diet group; OGTT, oral glucose tolerance
test; The values are presented as the means ± SEM, n = 12; *P < 0.05 vs. MD10% group; **P < 0.01 vs. MD10% group; ***P < 0.001 vs. MD10% group
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mRNA expression of these genes in the epididymal fat tis-
sue was not affected by miR-130b-MV treatment. Never-
theless, it remains to be determined whether these genes
are affected at the level of protein.
We further investigated the down-stream molecular
mechanisms underlying the miR-130b-MV-mediated in-
hibition in fat deposition. FAS and ACC are key adipogenic
enzymes [38] that play pivotal roles in fat deposition, while
HSL, ATGL and MGL are important lipases responsible
for TG hydrolysis [39, 40]. Leptin, a cytokine secreted
predominantly from the fat tissue, plays an important
role in regulating energy balance, and increased leptin
can stimulate lipolysis, by up-regulating HSL, ATGL
and MGL expression [41]. In the present study, miR-130b-
MV increased HSL, MGL and leptin mRNA expression,
but did not influence FAS and ACC mRNA expression.
Therefore, it is presumed that miR-130b-MV decreases
fat deposition predominantly by enhanced lipolysis but
not lipogenesis.
It is noted that miR-130b-MV also altered the expression
of other miRNAs related to fat deposition. For instance,
miR-378a and miR-378b-3p were up-regulated significantly
in the epididymal fat tissue of miR-130b-MV-injected mice.
miR-378 is highly induced during adipogenesis and has
been reported to be positively regulated in adipogenesis.
The role of miR-378 family in fat deposition has been
Table 3 Effect of miR-130b-MV injection for 10 days on the apparent and blood biochemical parameters in mice
Parameters HF-SC-MV HF-130b-MV P Value
Sampling parameters
Body weight (g) 29.75 ± 0.53 26.30 ± 0.90 0.000
Epididymal fat weight (mg) 1.02 ± 0.09 0.72 ± 0.09 0.034
Liver weight (mg) 1.18 ± 0.05 1.17 ± 0.06 0.822
Muscle weight (mg) 0.34 ± 0.02 0.29 ± 0.01 0.025
Epididymal fat weight/Body weight 0.034 ± 0.003 0.027 ± 0.003 0.063
Liver weight/Body weight 0.039 ± 0.002 0.045 ± 0.002 0.004
Muscle weight/Body weight 0.011 ± 0.005 0.011 ± 0.005 0.825
Biochemical parameters
ALT (U/L) 10.83 ± 1.72 10.45 ± 1.84 0.882
AST (U/L) 53.64 ± 5.68 52.50 ± 2.00 0.858
GLU (mmol/L) 11.92 ± 0.60 10.13 ± 0.74 0.074
TG (mmol/L) 0.55 ± 0.04 0.44 ± 0.04 0.109
Tch (mmol/L) 2.59 ± 0.13 2.41 ± 0.14 0.334
HDLc (mmol/L) 1.46 ± 0.08 1.33 ± 0.05 0.167
LDLc (mmol/L) 0.15 ± 0.02 0.20 ± 0.03 0.066
NEFA (μmol /L) 857.67 ± 41.17 879.82 ± 56.14 0.751
Hormones and cytokines
IL-6 (pg/mL) 69.94 ± 14.17 216.98 ± 96.37 0.163
Insulin (pg/mL) 1668.54 ± 243.60 1618.35 ± 223.44 0.881
Leptin (pg/mL) 2566.43 ± 421.64 2289.77 ± 550.37 0.698
TNF-α (pg/mL) 6.66 ± 0.48 7.81 ± 0.69 0.194
Notes: HF, high fat; HF-SC-MV, high fat diet induced obese mice injected with miR-SC-MV; HF-130b-MV, high fat diet induced obese mice injected with miR-130b-
MV; The values shown represent the means ± SEM; P < 0.05 means significant difference compared with the HF-SC-MV group; n = 12
(See figure on previous page.)
Fig. 3 Epididymal fat deposition, miR-130b and its target gene PPAR-γ expression. a: Flow chart depicting the experimental design. The obese C57BL/6
mice were injected via tail vein with miR-SC-MV or miR-130b-MV every other day for 10 days. miR-130b-MV was harvested by transfecting HeLa-229 cells
with miR-130b plasmid. Ten days later, the mice were weighed and sampled. b: Gene expression of miR-130b in miR-130b-MV. c: Body sizes.
d-e: Epididymal fat sizes. f-g: Epididymal fat weight and the ratio between epididymal fat weight and body weight. h: Expression of miR-130b
gene in the epididymal fat. i: mRNA expression of the miR-130b target genes. j: mRNA expression of the miR-130b target gene PPAR-γ. k: Protein
expression of miR-130b target gene PPAR-γ. HF, high fat; HF-SC-MV, high-fat diet-induced obese mice injected with miR-SC-MV; HF-130b-MV, high-fat
diet-induced obese mice injected with miR-130b-MV; The values shown represent the means ± SEM, n = 12; *P < 0.05 vs. HF-SC-MV group; **P < 0.01 vs.
HF-SC-MV group
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controversial. Over-expression of miR-378 was shown to
increase fat accumulation [42], yet the opposite result was
also reported [43]. Over-expression of miR-378 increased
lipolysis genes expression, while inhibition of miR-378 ex-
pression attenuated stimulated lipolysis and reduced the
expression of lipolytic regulators [44]. MVs have been uti-
lized for the delivery of therapeutic RNAi and are consid-
ered as a more effective, advantageous method than other
options. Compared with the delivery strategies of viruses,
lipid nanoparticles and polymeric nanoparticles, MVs
present some major advantages. MVs are natural carriers
and are not subjected to the attacks by antibodies, comple-
ments or opsonins in circulation. Other methods are prone
to be cleared or trigger unwanted immune responses [45].
In the present study, MVs delivered miR-130b into the
epididymal fat tissue efficiently and repressed the fat de-
position, further suggesting that MVs are advantageous
carriers for transferring therapeutic small RNAs compared
to other methods. However, miR-130b-MV injection was
conducted every other day for 10 days due to limited
quantity of the miR-130b-MV preparations. The effects
and the side-effects, if any, of prolonged treatment of
miR-130b-MV remain unclear. It was reported that 7 days
after miR-150b-MV injection, miR-150 still maintained at
a low level in plasma, and its target gene VEGF was re-
pressed and the tumor development was also suppressed
[46]. Future studies are required to test the half-life of
MV-protected miR-130b.
Conclusion
In summary, this is the first in vivo study demonstrating
that miR-130b-MV can be shuttled into the epididymal
fat tissue to down-regulate PPAR-γ expression and to
stimulate the expression of lipolysis genes. Further studies
may be directed to assess the cytotoxicity and the half-life
of miR-130b-MV in the blood, so as to further contribute
to the development of anti-obesity drugs for clinical
application.
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